Skip to main content

FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July

Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.